RenovoRx Chief Clinical Officer, Leesa Gentry, will be a speaker at #ResearchRevolution2025 taking place October 26th - 28th, 2025 in Atlanta, GA. The event brings together industry leaders to discuss innovations that are shaping the future of clinical research, learn more: https://bit.ly/4nmpwNN #ClinicalTrials #ClinicalResearch
RenovoRx (Nasdaq: RNXT)
Biotechnology Research
Mountain View, California 3,048 followers
Delivering Therapy Where it Matters™
About us
RenovoRx, Inc. (Nasdaq: RNXT) is developing innovative targeted oncology therapies and commercializing RenovoCath®, a novel, U.S. FDA-cleared local drug-delivery device, targeting high unmet medical needs. RenovoRx’s patented Trans-Arterial Micro-Perfusion (TAMP™) therapy platform is designed for targeted therapeutic delivery across the arterial wall near the tumor site to bathe the target tumor, while potentially minimizing a therapy’s toxicities versus systemic IV therapy. RenovoRx’s novel approach to targeted drug-delivery offers the potential for increased safety, tolerance, and improved efficacy, and its mission is to transform the lives of cancer patients by providing innovative solutions to enable targeted delivery of diagnostic and therapeutic agents. RenovoRx is evaluating its novel drug-device combination oncology product candidate (intra-arterial gemcitabine delivered via RenovoCath, known as IAG) in the ongoing Phase III TIGeR-PaC trial. IAG is being evaluated by the Center for Drug Evaluation and Research under a U.S. investigational new drug application that is regulated by the FDA’s 21 CFR 312 pathway. IAG utilizes RenovoCath which is indicated for temporary vessel occlusion in applications including arteriography, preoperative occlusion, and chemotherapeutic drug infusion. IAG is currently under investigation and has not been approved for commercial sale. RenovoRx is actively commercializing its TAMP technology and RenovoCath as a stand-alone device. In Dec. 2024, RenovoRx announced the receipt of its first commercial purchase orders for RenovoCath devices. Several of these customers have already initiated repeat orders in parallel to RenovoRx expanding the number of medical institutions initiating new RenovoCath orders, including several esteemed, high-volume NCI-designated centers. To meet and satisfy the anticipated demand, RenovoRx will continue to actively explore further revenue-generating activity.
- Website
-
http://www.renovorx.com
External link for RenovoRx (Nasdaq: RNXT)
- Industry
- Biotechnology Research
- Company size
- 2-10 employees
- Headquarters
- Mountain View, California
- Type
- Public Company
Locations
-
Primary
Get directions
2570 W El Camino Real
Ste. 320
Mountain View, California 94040, US
Employees at RenovoRx (Nasdaq: RNXT)
-
Joyo Wijaya
Investor
-
Sharon Vosmek
CEO & Managing Partner. Series A/B Investor, Board Member, Advisor, Speaker, fierce advocate for my portfolio and champion of teams that include…
-
Robert Strasser
Vice President Operations and R&D
-
Ryan Witt
Serving principally healthcare & life science entities. At times, active in public policy and community building. Patient advocate & family…
Updates
-
RenovoRx will host the TAMP (Trans-Arterial Micro-Perfusion) Peer-to-Peer Best Practices Workshop on Tuesday, November 4th at 5:00 PM PT, with cases presented by Dr. Ripal Gandhi and Dr. Juan Camacho Vasquez. This educational workshop is an interactive peer-to-peer forum designed for physicians to share their experiences, including case presentations, with the TAMP therapy platform, enabled by the RenovoCath® device. Register for the workshop here: https://bit.ly/49doAYj
-
-
Dr. Ripal Gandhi, interventional radiologist at Miami Cancer Institute, will present during Session 5: "What’s New and Hot: Emerging Therapies and New Technologies" at #CIO2025 tomorrow, October 18th. Dr. Gandhi will discuss the latest advances in oncology therapies and highlight RenovoRx’s patented Trans-Arterial Micro-Perfusion (TAMP™) platform, designed for targeted drug-delivery via the RenovoCath® device, while potentially minimizing a therapy’s toxicities versus systemic intravenous therapy. For event details: https://bit.ly/46KJ7Aj
-
-
We are pleased to welcome internationally renowned interventional oncologist, Thierry de Baère, MD, PhD, to RenovoRx’s Scientific Advisory Board. Dr. de Baère is a leading expert on targeted drug-delivery and locoregional cancer therapies, learn more: https://bit.ly/4717k6c
-
-
“Professor de Baère is an internationally recognized clinical expert and researcher who has made pioneering contributions to the field of interventional oncology, and we are honored to have him join our SAB,” said Ramtin Agah, MD, Chief Medical Officer and Founder of RenovoRx. https://bit.ly/4717k6c
-
-
RenovoRx today announced the appointment of internationally renowned interventional oncologist Thierry De Baere, MD, PhD to RenovoRx’s Scientific Advisory Board (SAB). Professor de Baère is a leading expert on targeted drug-delivery and locoregional cancer therapies, and his expertise will further strengthen our SAB. Learn more: https://bit.ly/4717k6c
-
-
The 20th Clinical Trials Strategic Summit kicks off today! RenovoRx Chief Clinical Officer, Leesa Gentry, will participate in a panel discussion tomorrow, October 9th at 12:45 p.m. PT. For event details: https://bit.ly/3VJVQP8 #CTSS2025 #ClinicalResearch #ClinicalTrials
-
-
Our CEO, Shaun R. Bagai, recently joined The Living Hope Podcast to discuss RenovoRx’s patented Trans-Arterial Micro-Perfusion (TAMP™) therapy platform designed for targeted drug-delivery via the RenovoCath® device, while potentially minimizing a therapy’s toxicities versus systemic intravenous therapy. Shaun also discussed advancements in the ongoing Phase III TIGeR-PaC clinical trial in #LocallyAdvancedPancreaticCancer. Listen here: https://bit.ly/4gSnwLh
-
-
RenovoRx CEO, Shaun R. Bagai, spoke with PharmaShots about recent corporate milestones. Milestones include expanding the Company’s IP portfolio, progress in commercialization efforts for RenovoCath® as a standalone targeted drug-delivery device, and advancements in the Phase III TIGeR-PaC clinical trial in locally advanced pancreatic cancer and the PanTheR Post-Marketing Registry Study evaluating drug-delivery via RenovoCath to solid tumors. Read more: https://bit.ly/489N84f
-
RenovoRx Chief Clinical Officer, Leesa Gentry, will participate in a panel discussion focused on designing clinical trials optimized for performance at the 20th Clinical Trials Strategic Summit, taking place October 8th - 9th, 2025 in San Francisco, CA. For event details: https://bit.ly/3VJVQP8 #CTSS2025 #ClinicalResearch #ClinicalTrials
-